AstraZeneca delivered strong financial results for the first nine months of 2025, with Total Revenue up 11% at constant exchange rates to $43,236 million and Core EPS rising 15% to $7.04, driven by consistent growth across all therapy areas and regions. Oncology revenue rose by 16%, while Respiratory & Immunology advanced 13%, reflecting the company’s diversified pipeline and commercial execution.
The company announced 16 positive Phase III readouts so far this year—four in the last quarter—including notable successes for baxdrostat in hypertension and Enhertu and Datroway in breast cancer. Regulatory milestones included key global trial readouts, approvals, and submissions for leading medicines like Enhertu, Datroway, Imfinzi, Lynparza, and others.
AstraZeneca’s CEO Pascal Soriot highlighted strategic progress in the U.S., emphasizing a landmark agreement with the U.S. government aimed at lowering drug costs for American patients. The company also broke ground in October on a $4.5 billion manufacturing facility in Virginia as part of its $50 billion U.S. investment and expansion plan, with the new site expected to generate about 3,600 jobs and support production of drugs for weight management, metabolic disease, as well as oncology antibody drug conjugates.
AstraZeneca reiterated its full-year 2025 guidance for high single-digit Total Revenue growth and low double-digit Core EPS growth at constant exchange rates, expecting trends to continue if current foreign exchange rates persist through year-end. The company also announced a global listing structure, enabling share trading across London, Stockholm, and New York starting February 2026.
Additional updates included the completed acquisition of SixPeaks Bio AG for potential weight management therapies and a revised global agreement with Merck over Koselugo, in which AstraZeneca now recognizes all revenues and profits for the product worldwide. Sustainability rankings continued to bolster the company’s profile, as it maintained its position as the top pharmaceutical company for sustainability transparency, according to TIME Magazine.
AstraZeneca’s next quarterly and full-year results update is scheduled for February 10, 2026.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!